agilon health, inc. (AGL): Results of Operations and Financial Condition
agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Second Quarter 2026 Results Revenue increase 7% to $1.49 billion Raises Full-Year 2026 Total Revenues, Medical Margin, and Adjusted EBITDA Guidance Westerville, O.H., August 5, 2026 – agilon health, inc. (NYSE: AGL), the trusted partner empoweri
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY2026 guidance ranges and the Q2 profitability improvements (gross profit, medical margin, Adjusted EBITDA) versus the prior year period.
Market read
Guidance and profitability metrics are updated in a primary filing, creating a direct catalyst for earnings-model repricing.
What to watch
Medical margin includes favorable claims development, and ACO model entities are not consolidated, which can complicate GAAP-to-non-GAAP interpretation.
Revenue increase 7% to $1.49 billion; raises full-year 2026 Total Revenues, Medical Margin, and Adjusted EBITDA guidance.
Second-quarter revenue increased 7%, while gross profit, net income, medical margin, and Adjusted EBITDA all moved from losses in the prior-year quarter to positive results. The company also raised full-year Total Revenues, Medical Margin, and Adjusted EBITDA guidance despite lower year-over-year platform membership.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Medicare Advantage Membersother | 437,000 | – | (12%) |
| ACO Model Membersother | 112,000 | – | (3%) |
| Total Members Live on Platformother | 549,000 | – | (10%) |
| Avg. Medicare Advantage Membersother | 447,000 | – | (10%) |
| Total RevenuesGAAP | $1,495 | – | 7% |
| Gross Profit (Loss)GAAP | $107 | – | NM |
| Medical Marginnon-GAAP | $197 | – | NM |
| Net Income (Loss)GAAP | $18 | – | NM |
| Adjusted EBITDAnon-GAAP | $70 | – | NM |
| Geography Entry Costsother | $4 | – | (20%) |
| ACO model entities contribution to Adjusted EBITDAnon-GAAP | $7 million | – | – |
Fiscal Year 2026 and Third Quarter 2026 outlook
- RevenueFiscal Year 2026, Low: $5,775; High: $5,860. Third Quarter 2026, Low: $1,445; High: $1,475.
- NoteFiscal Year 2026 Medicare Advantage Members, Low: 435,000; High: 445,000.
- NoteFiscal Year 2026 ACO REACH Members, Low: 100,000; High: 105,000.
- NoteFiscal Year 2026 Total Members Live on Platform, Low: 535,000; High: 550,000.
- NoteFiscal Year 2026 Avg. Medicare Advantage Members, Low: 438,000; High: 443,000.
- NoteFiscal Year 2026 Medical Margin, Low: $465; High: $505.
- NoteFiscal Year 2026 Adjusted EBITDA, Low: $75; High: $95.
- NoteFiscal Year 2026 Geography Entry Costs, Low: $15; High: $15.
- NoteAdjusted EBITDA contribution from ACO model entities is expected to be approximately $25-$30 million for fiscal year 2026.
- NoteThird Quarter 2026 Medicare Advantage Members, Low: 433,000; High: 443,000.
- NoteThird Quarter 2026 ACO REACH Members, Low: 106,000; High: 109,000.
- NoteThird Quarter 2026 Total Members Live on Platform, Low: 539,000; High: 552,000.
- NoteThird Quarter 2026 Avg. Medicare Advantage Members, Low: 445,000; High: 455,000.
- NoteThird Quarter 2026 Medical Margin, Low: $105; High: $115.
- NoteThird Quarter 2026 Adjusted EBITDA, Low: ($5); High: $5.
- NoteThird Quarter 2026 Geography Entry Costs, Low: $6; High: $6.
- NoteAn expected increase year-over-year in member risk scores of 3% net of v28.
- NoteEstimated cost trends in the low 7% range for the remainder of the year.
What drove it
- Revenue was favorable due to higher than expected burden of illness performance, payor contracting, and improved pricing, partially offset by lower year-over-year membership.
- Medical margin included favorable first quarter 2026 and prior year claims development.
- Full-year revised guidance reflects second quarter 2026 performance, an expected increase year-over-year in member risk scores of 3% net of v28, and estimated cost trends in the low 7% range for the remainder of the year.
- Year-over-year membership changes primarily reflect a disciplined approach to contracting focused on profitability, previously disclosed market exits, and a measured approach to growth.
Concerns
- Total Members Live on Platform decreased (10%) year over year to 549,000.
- Medicare Advantage Members decreased (12%) year over year to 437,000.
- The third-quarter Adjusted EBITDA outlook is Low: ($5); High: $5.
- The company cited estimated cost trends in the low 7% range for the remainder of the year.
What to watch
- Execution against the Fiscal Year 2026 Medical Margin outlook of Low: $465; High: $505.
- Execution against the Fiscal Year 2026 Adjusted EBITDA outlook of Low: $75; High: $95.
- Membership relative to the Fiscal Year 2026 Total Members Live on Platform outlook of Low: 535,000; High: 550,000.
- Third-quarter medical margin outlook of Low: $105; High: $115 and Adjusted EBITDA outlook of Low: ($5); High: $5.
- Progress in member risk scores, expected to increase year over year by 3% net of v28, and medical cost trends.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities of $257 million as of June 30, 2026.
- Total debt of $32 million as of June 30, 2026.
- Cash associated with the Company’s unconsolidated ACO model entities of $83 million at the end of the quarter.
Analysis
agilon reported $1,495 of Total Revenues for the second quarter of 2026, up 7% from $1,395 in the second quarter of 2025. The release attributed favorable revenue to higher than expected burden of illness performance, payor contracting, and improved pricing, partially offset by lower year-over-year membership. The reported membership base was lower across each disclosed category, including 437,000 Medicare Advantage Members, 112,000 ACO Model Members, and 549,000 Total Members Live on Platform.
Profitability improved substantially from the prior-year quarter. Gross Profit (Loss) was $107 versus $(52), Net Income (Loss) was $18 versus $(104), Medical Margin was $197 versus $(53), and Adjusted EBITDA was $70 versus $(83). The company said Medical Margin included favorable first quarter 2026 and prior year claims development. Geography Entry Costs declined to $4 from $5.
The company ended the quarter with cash, cash equivalents and marketable securities of $257 million and total debt of $32 million. It also reported $83 million of cash associated with unconsolidated ACO model entities. No operating cash flow, free cash flow, repurchases, dividends, or other capital-return activity was reported in the provided document.
Management raised its fiscal-year outlook. Fiscal Year 2026 Total Revenues guidance is Low: $5,775; High: $5,860, Medical Margin is Low: $465; High: $505, and Adjusted EBITDA is Low: $75; High: $95. The third-quarter outlook calls for Total Revenues of Low: $1,445; High: $1,475, Medical Margin of Low: $105; High: $115, and Adjusted EBITDA of Low: ($5); High: $5. The guide assumes an expected increase year-over-year in member risk scores of 3% net of v28 and estimated cost trends in the low 7% range for the remainder of the year.
Management, verbatim
Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.
Tim O’Rourke, Chief Executive Officer of agilon health
We are raising our full-year 2026 outlook which reflects stronger burden of illness execution, favorable medical cost trends, and continued operating discipline.
Tim O’Rourke, Chief Executive Officer of agilon health
Not in the filing
stated, not guessed- GAAP EPS and non-GAAP EPS.
- Operating income or loss.
- Gross margin.
- Operating expenses.
- Tax rate.
- Operating cash flow.
- Free cash flow.
- Share repurchases and dividends.
- Revenue by operating segment.
- Prior-quarter comparisons for reported second-quarter metrics.
- Forward-looking gross profit or loss and net income or loss guidance.
- Prior outlook section as a separate prior release for guidance-versus-actual comparison.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 operating results and revised FY2026 and Q3 2026 guidance.
Ticker impact
agilon health reported Q2 2026 results and raised full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
Likely positive near-term bias as guidance increases and Q2 profitability inflects, though member declines and ACO non-consolidation may temper upside.
The filing includes specific Q2 financial improvements and explicit updated FY2026 ranges for revenues, medical margin, and Adjusted EBITDA, which are direct valuation inputs for the stock.
Market effects
Provides a read-through on value-based care execution and medical cost trends for managed care and healthcare services peers.
Limited, primarily US healthcare services sentiment.
Low, company-specific US filing.
Counterpoint
Member counts declined (total members down 10% YoY), so the guidance raise may rely on cost and pricing improvements rather than sustained growth.
Key entities
- companyagilon health, inc.
Reported Q2 2026 results and increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
- executiveTim O’Rourke
CEO quoted on progress across strategic initiatives and confidence in the Total Care Model.
